Investorideas.com


Be a guest or sponsor our podcasts - learn more about us : 800 665 0411

 


BiotechIndustryStocks.com - A Leading Global Investor Website for Biotech Industry Stocks

BiotechIndustryStocks.com - investing ideas in biotechnology stocks, medical technology and life sciences

Like Biotech Stocks? View our Biotech Stocks Directory    Get News Alerts on Biotech Stocks


Featured Biotech stocks - Feature Your Company & Product Here

Biotech News

Global Healthcare to Soar Above $2 Trillion in 2020 with Consumerism and Outcome-based Care Models
Santa Clara, Calif. - February 18, 2020 (Investorideas.com Newswire) Despite rising trade tension and a sluggish economic outlook for 2020, the global healthcare industry is set for an invigorating year due to a partial realization of major healthcare policies and initiatives and technology advancements.

Biotech Stock News Bites: Evelo Biosciences (NASDAQ: $EVLO) Reports Fourth Quarter and Full Year 2019 Financial Results and Business Highlights
February 14, 2020 (Investorideas.com Newswire) Investorideas.com (www.investorideas.com) Biotechnology Stock News Bites- CAMBRIDGE, Mass.,Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, reported on the close yesterday, financial results and business highlights for the fourth quarter and full year 2019.

Cancer Therapies Stock News Bites: ImmunoGen (NASDAQ: $IMGN) Reports Recent Progress and 2019 Financial Results
February 14, 2020 (Investorideas.com Newswire) Investorideas.com (www.investorideas.com) Cancer Therapies Stock News Bites- WALTHAM, Mass - ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter and year ended December 31, 2019.

Biotech Stock News: CytoDyn (OTCQB: $CYDY) Signs Letter of Intent for the Joint Development and Licensing of Leronlimab in China with Longen China Group
VANCOUVER, Washington - February 12, 2020 (Investorideas.com Newswire) CytoDyn Inc. (OTC.QB: CYDY), ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that the Company signed a nonbinding letter of intent (LOI) for the joint development and licensing of leronlimab in China with Longen China Group ("Longen").

Pharma Stock News: New Report Shows Teva (NYSE: $TEVA) (TASE: TEVA) Generic Medicines Saved US Healthcare System $41.9 Billion
TEL AVIV, Israel & PARSIPPANY, N.J - February 12, 2020 (Investorideas.com Newswire) Teva Pharmaceutical Industries Ltd. (NYSE: TEVA and TASE: TEVA) released a new economic impact report detailing the billions of dollars saved by Teva's generic medicines and the company's impact on the US and global economies in 2018.

Gene Therapy Stock News: Genprex (NASDAQ: $GNPX) and University of Pittsburgh Sign Exclusive License Agreement for Potentially Curative Gene Therapy Candidate for Diabetes
February 11, 2020 (Investorideas.com Newswire) Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and other serious diseases, today announced that it signed an exclusive license agreement with the University of Pittsburgh for a diabetes gene therapy that may have the potential to cure Type 1 and Type 2 diabetes

vTv Therapeutics' Shares open 80% Higher on Phase 2 Type 1 Diabetes Trial Data
February 11, 2020 (Investorideas.com Newswire) Shares of vTv Therapeutics traded 50% higher after the company reported positive results from Part 2 of the Phase 2 Simplici-T1 Study of TTP399 used in the treatment of patients with type 1 diabetes.

Biopharma Stock News: Zai Lab (NASDAQ: $ZLAB) Announces Acceptance of NDA Submission of Omadacycline in China by the NMPA
SHANGHAI, China and SAN FRANCISCO - February 11, 2020 (Investorideas.com Newswire) Zai Lab Limited (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, announced that the China National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for omadacycline for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI).

Myriad Genetics Shares Fall 30% on Q2 Earnings and Executive Leadership Change
February 10, 2020 (Investorideas.com Newswire) Shares of Myriad Genetics traded 30% lower after the firm released Q2/20 earnings and announced the appointment of a new interim CEO.

Biotech Stock News: Generex Biotechnology (OTCQB: GNBT) Announces Corporate Update and Investor Conference Call: Addressing the #Coronavirus Pandemic with Ii-Key Peptide Vaccines - Thursday February 13
MIRAMAR, Fla. - February 10, 2020 (Investorideas.com Newswire) Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced that Joe Moscato, President & Chief Executive Officer and the team from NuGenerex Immuno-Oncology will hold an investor conference call on Thursday February 13, 2020 at 11:00 AM Eastern time.

Subscribe to Biotech News RSS

Submit Articles   Search More Articles

Biotech Stock ETF's

First Trust NYSE Arca Biotech ETF ( NYSEArca: FBT ) The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE Arca Biotechnology Index(SM). The fund will normally invest at least 90% of its net assets plus the amount of any borrowings for investment purposes in common stocks that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. The fund is non-diversified.

iShares US Healthcare ( NYSEArca: IYH ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Health Care Index (the "underlying index"), which measures the performance of the healthcare sector of the U.S. equity market. The fund is non-diversified.

iShares US Healthcare Providers ( NYSEArca: IHF ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare providers sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Select Health Care Providers Index (the "underlying index"), which measures the performance of the healthcare providers sector of the U.S. equity market. The fund is non-diversified.

iShares US Medical Devices ( NYSEArca: IHI ) The investment seeks to track the investment results of an index composed of U.S. equities in the medical devices sector. The fund seeks to track the investment results of the Dow Jones U.S. Select Medical Equipment Index (the "underlying index"), which measures the performance of the medical equipment sector of the U.S. equity market. The underlying index includes medical equipment companies such as manufacturers and distributors of medical devices such as magnetic resonance imaging (MRI) scanners, prosthetics, pacemakers, X-ray machines, and other non-disposable medical devices. The fund is non-diversified.

iShares Nasdaq Biotechnology ( NasdaqGIDS IBB ) The investment seeks to track the investment results of an index composed of biotechnology and pharmaceutical equities listed on the NASDAQ. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. The underlying index contains securities of NASDAQ® listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by the NASDAQ OMX Group, Inc. The fund is non-diversified.

Market Vectors Biotech ETF ( NYSE MKT:BBH ) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Market Vectors® US Listed Biotech 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index is comprised of common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology sector. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

PowerShares Dynamic Biotech & Genome ETF ( NYSEArca: PBE ) The investment seeks investment results that generally correspond (before fees and expenses) to the price and yield of the Dynamic Biotechnology & Genome IntellidexSM Index. The fund generally will invest at least 90% of its total assets in common stocks of biotechnology companies and genome companies that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of 30 U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.

Biotech News from Newsfile

Media Central Corporation Inc. Completes Shares for Debt Transaction
Toronto, Ontario--(Newsfile Corp. - January 31, 2020) - Media Central Corporation Inc. (CSE: FLYY) (FSE: 3AT) ("MediaCentral" or the "Company") reports that its Board of Directors has approved the settlement of $271,200 in aggregate of debt through the issuance of common shares of the Company (the "Debt Settlement"). Pursuant to the Debt Settlement, MediaCentral would issue 3,190,588 common shares of the Company (the "Shares") at a deemed price of $0.085 per Share to certain creditors...

American Aires Announces Agreement with Answer 365 and to Partner with Four Fulfillment Centers
Toronto, Ontario--(Newsfile Corp. - January 31, 2020) - American Aires Inc. (CSE: WIFI) (the "Company" or "Aires") is pleased to announce that it has entered into a call centre service agreement (the "Service Agreement") effective January 28, 2020 with Answer 365, a Canadian call center, pursuant to which Answer 365 will outsource Aires' customer service providing 24-hour support and increased purchase satisfaction for Aires' customers around the world.. The Service Agreement may be terminated by...

EGF Theramed Announces Change of Directors and New CEO
Vancouver, British Columbia--(Newsfile Corp. - January 30, 2020) - EGF Theramed Health Corp. (CSE: TMED) has appointed David Bentil and Jatinder Dhaliwal to the board of EGF Theramed Health Corp. Mr. Bentil will assume the role of CEO and Mr. Dhaliwal will assume the role of director. Mr. Bentil is an Economist by trade. In 2002, he decided to follow his passion by pursuing a career in the car business which has done for over...

Rainmaker Worldwide and Pi Eco Announce a Strategic Investment and Global Reseller Agreement
Peterborough, Ontario--(Newsfile Corp. - January 30, 2020) - Rainmaker Worldwide Inc. (OTC Pink: RAKR) is extremely pleased to announce a comprehensive strategic investment by Pi Eco USA (www.pi.eco). This investment brings working capital for Rainmaker to fuel growth and upcoming deployments.In addition to the 500,000 USD capital injection, Pi Eco provides distributor and executive synergies that will be invaluable to Rainmaker and Pi Eco. Pi Eco has well-developed strategic relationships in Asia, Middle East, Central...

Cell MedX Corp. Reacquires World Wide Exclusivity Rights for the eBalance(R) Device
Carson City, Nevada--(Newsfile Corp. - January 30, 2020) - Cell MedX Corp. (OTCQB: CMXC) (MUN: 9CX) ("Cell MedX" or the "Company"), a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, is pleased to announce that the Company has repurchased the worldwide exclusive direct rights for distribution of its eBalance® devices.Cell MedX identified two distribution market channels for sales of the eBalance® device, individual rights for home...

Subscribe to Biotech News

Biotech/ Pharma Stock Directory

Preview

4SC (XETRA: VSC.DE) is an innovative biotech company with a strong focus on clinical development. We discover and develop targeted small molecule drugs with an epigenetic mode of action for the treatment of cancer in indications with a high unmet medical need and major economic potential.

Aastrom Biosciences, Inc. (NasdaqCM: ASTM) is the leader in developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. Aastrom markets two autologous cell therapy products in the United States for the treatment of cartilage repair and skin replacement. Aastrom is also developing MACI(TM), a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee, and ixmyelocel-T, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy.

ABBOTT LABORATORIES (NYSE: ABT) is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. With a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals, Abbott serves people in more than 150 countries and employs approximately 69,000 people.76

Abeona Therapeutics Inc. (NasdaqCM:ABEO) develops and delivers gene therapy and plasma-based products for severe and life-threatening rare diseases. Abeona's lead programs are AB0-101 (AAV NAGLU) and ABO-102 (AAV SGSH), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (MPS IIIB and IIIA). We are also developing ABO-201 (AAV CLN3) gene therapy for juvenile Batten disease (JBD); and ABO-301 (AAV FANCC) for Fanconi anemia (FA) disorder using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. In addition, we are also developing rare plasma protein therapies including SDF Alpha™ (alpha-1 protease inhibitor) for inherited COPD using our proprietary SDF™ (Salt Diafiltration) ethanol-free process.

Ablynx (Brussels: ABLX.BR) is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious and life-threatening human diseases, including inflammation, thrombosis, oncology and pulmonary disease.

Acadia Pharmaceuticals Inc. (NasdaqGS: ACAD) is a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders. ACADIA has a pipeline of product candidates led by pimavanserin, for which we have reported positive Phase III trial results in Parkinson's disease psychosis and which has the potential to be the first drug approved in the United States for this disorder. We are currently completing NDA-enabling clinical and manufacturing activities for pimavanserin and are planning to submit an NDA with the FDA near the end of 2014. Pimavanserin is also in Phase II development for Alzheimer's disease psychosis and has successfully completed a Phase II trial in schizophrenia. ACADIA also has clinical-stage programs for chronic pain and glaucoma in collaboration with Allergan, Inc. and two preclinical programs directed at Parkinson's disease and other neurological disorders. All product candidates are small molecules that emanate from internal discoveries.

Access Pharmaceuticals, Inc. (OTC:ACCP) is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access developed MuGard and ProctiGard and is developing multiple follow-on products. Access also has other advanced drug delivery technologies including CobaCyte™-mediated targeted delivery and CobOral-oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism.

AcelRx Pharmaceuticals, Inc. (NasdaqGM:ACRX) is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company's late-stage pipeline includes ARX-04 (sufentanil sublingual tablet, 30 mcg), designed for the treatment of moderate-to-severe acute pain in medically supervised settings; and Zalviso® (sufentanil sublingual tablet system), designed for the management of moderate-to-severe acute pain in adult patients in the hospital setting. Zalviso delivers 15 mcg sufentanil sublingually through a non-invasive delivery route via a pre-programmed, patient-controlled analgesia device. Zalviso is approved in the EU as well as Norway, Iceland, and Liechtenstein and is investigational and in late-stage development in the U.S. Grunenthal Group holds the rights for Zalviso in Europe and Australia, while AcelRx retains all other world-wide rights.

Acorda Therapeutics, Inc. (NasdaqGS:ACOR) is a biotechnology company focused on developing therapies that improve the lives of people with neurological disorders. Acorda markets three FDA-approved therapies including: AMPYRA (dalfampridine) Extended Release Tablets, 10 mg, a treatment to improve walking in patients with multiple sclerosis (MS); ZANAFLEX CAPSULES® (tizanidine hydrochloride) and Zanaflex tablets, a short-acting drug for the management of spasticity; and QUTENZA® (capsaicin) 8% Patch, for the management of neuropathic pain associated with postherpetic neuralgia. AMPYRA is marketed outside the United States as FAMPYRA® (prolonged-release fampridine tablets) by Biogen Idec under a licensing agreement from Acorda. Acorda has one of the leading pipelines in the industry of novel neurological therapies. The Company is currently developing six clinical-stage therapies and one preclinical stage therapy that address a range of disorders including post-stroke deficits, epilepsy, stroke, peripheral nerve damage, spinal cord injury, neuropathic pain, and heart failure.

Acrux Limited (ASX:ACR.AX) is a dynamic Australian drug delivery business developing and commercialising a range of patient-preferred pharmaceutical products for global markets, using innovative, patented technology to administer drugs through the skin. Fast drying, non-occlusive topical sprays or liquids provide an enhanced transdermal delivery platform with low or no skin irritation, superior cosmetic acceptability, and simple, accurate and flexible dosing.

See the full stock directory here

Sponsored Financial Content and Guest Posts

Buy a guest post on Investorideas.com

The Rise Of The At-Home Testing Market

January 16, 2020 (Investorideas.com Newswire) Have you heard the term personalized medicine? It's the buzzword in use today thanks to the increase in medical tests being conducted at home.

Why Do You Need Birth Injury Lawyer and How They Can Help You?

October 2, 2019 (Investorideas.com Newswire) Childbirth injury is inexcusable. From the moment a child is conceived to the time the delivery is done, it is the responsibility of the doctors to see that the child is delivered with the utmost care and is healthy.

5 Key Tips For Renting a Boardroom

August 14, 2018 (Investorideas.com Newswire) You've arranged to rent virtual offices in Toronto from time to time.

How to Go About Choosing a Medical Malpractice Lawyer

February 13, 2018 (Investorideas.com Newswire) Medical malpractice affects thousands of individuals around the world. If you think you have been injured, or wrongfully treated by a medical professional, you may be entitled to compensation.